Richard Buka/X
Sep 23, 2025, 06:40
Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
Richard Buka, Chair of HaemSTAR, shared on X:
”Bit of pharma news here. CSL Behring have announced a colab with Dutch biotech, VarmX.
VarmX have been working on a very exciting molecule that is an antidote oral FXa inhibitors like rivaroxaban and apixaban.
What is this molecule? And why is it worth a potential $1.7bn?”
Stay updated with Hemostasis Today.
-
Feb 20, 2026, 17:35Wolfgang Miesbach: Plasma FIX Is Only Part of the Story In Haemophilia B
-
Feb 20, 2026, 17:27Sheharyar Raza: Examining Guideline Discordance in Evidence-Based Apheresis Recommendations
-
Feb 20, 2026, 17:23Barbara Mora: Newly Discovered EPO Gene Intronic Variant as a Cause of Congenital Erythrocytosis
-
Feb 20, 2026, 16:48Miguel Brito: Newborn Screening and Challenges in Follow-Up Care for Sickle Cell Disease in Angola
-
Feb 20, 2026, 16:41Uche Kennedy: Hemophilia Care Needs Systems Reform, Not Short-Term Fixes
-
Feb 20, 2026, 16:33Sonal Sonu: Real Clinical Maturity is Knowing When to Stop
-
Feb 20, 2026, 16:27Clear Recommendations for Daily Management and Family Support in Hemophilia A – WFH
-
Feb 20, 2026, 15:56Alan Nurden: Highlighting the Role of Activated Platelets in Heart and Kidney Complications of Diabetes
-
Feb 20, 2026, 15:51Domenico Girelli: Continuing Commitment to Rare Disease Research